Damora Therapeutics files Form 3 for director Jarrett

Damora Therapeutics, Inc. filed an initial insider ownership report for Jennifer Jarrett, who is listed as both a director and an officer (title noted as “See Remarks”).

Rhea-AI Filing Summary

Damora Therapeutics, Inc. filed an initial insider ownership report for Jennifer Jarrett, who is listed as both a director and an officer (title noted as “See Remarks”). This Form 3 does not report any stock purchases, sales, option exercises, or other transactions in Damora Therapeutics shares.

Key Terms

Form 3, reportingPersons, derivativeSummary

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": [ { "name": "Jarrett Jennifer""

derivativeSummary financial

""derivativeSummary": [],"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Damora Therapeutics (DMRA) Form 3 for Jennifer Jarrett show?

The Form 3 for Damora Therapeutics (DMRA) identifies Jennifer Jarrett as a director and officer. It serves as an initial insider ownership report and, in this excerpt, shows no stock purchases, sales, option exercises, or other transactions in DMRA securities.

Does the DMRA Form 3 for Jennifer Jarrett disclose any stock trades?

No, this DMRA Form 3 excerpt reports no stock trades by Jennifer Jarrett. The transaction summary shows zero buys, zero sells, zero option exercises, and no gifts or restructuring events, indicating only an initial reporting status without activity disclosed here.

What role does Jennifer Jarrett hold at Damora Therapeutics (DMRA) in this filing?

In this filing, Jennifer Jarrett is reported as both a director and an officer of Damora Therapeutics (DMRA). Her specific officer title is referenced as “See Remarks,” indicating that any detailed description of her role appears in the remarks section of the Form 3.

What is the purpose of this Damora Therapeutics (DMRA) Form 3 filing?

This Damora Therapeutics (DMRA) Form 3 serves as an initial statement of insider status for Jennifer Jarrett as a director and officer. It establishes her as a reporting person for SEC purposes, although the excerpt provided shows no related stock or derivative transactions.

Are there any derivative securities reported for Jennifer Jarrett in the DMRA Form 3?

No derivative securities are reported for Jennifer Jarrett in this DMRA Form 3 excerpt. The derivative summary is empty and the transaction summary lists zero derivative transactions, indicating no options, warrants, or similar instruments are shown here for her position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 05:24 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jarrett Jennifer

(Last) (First) (Middle)

C/O DAMORA THERAPEUTICS, INC.,

221 CRESCENT ST, BUILDING 23, SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/30/2026

3. Issuer Name and Ticker or Trading Symbol
Damora Therapeutics, Inc. [ DMRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

President and Chief Executive Officer Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Garrett Winslow, attorney-in-fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)